HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care, announced that a peer-reviewed article in JACC: Advances demonstrated that a risk prediction algorithm incorporating the credit card-sized HeartBeam ECG device can accurately identify heart attack risk in patients presenting with chest pain. The proof-of-concept study evaluated 184 patients and found that the algorithm achieved an “area under the curve” (AUC) of 86.5% using a single HeartBeam ECG reading combined with patient risk factors and symptoms, rising to 92.9% when a personal, symptom-free baseline ECG was available for comparison.
The company said the results support heart attack detection as a future indication for the HeartBeam System and advance its broader clinical program. The study, published in JACC: Advances, highlights the potential of the portable device to aid in early diagnosis of acute coronary syndrome, a leading cause of death worldwide. By enabling patients to record ECG signals outside of medical facilities, the technology could reduce time to treatment and improve outcomes.
HeartBeam’s platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. The company holds over 20 issued patents related to technology enablement. Its 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. The HeartBeam System with 12-Lead ECG synthesis software for arrhythmia assessment received FDA clearance in December 2025, and details on the intended use are available at https://www.heartbeam.com/indications.
The study’s findings are significant because chest pain is one of the most common reasons for emergency department visits, and rapid identification of heart attack risk is critical. Current diagnostic tools often rely on 12-lead ECGs performed in hospitals, which can delay care. HeartBeam’s credit card-sized device, which collects ECG signals in 3D from three non-coplanar directions and synthesizes them into a 12-lead ECG, offers a potential solution for remote monitoring and early detection.
For more details, the full press release is available at https://ibn.fm/ainxV. The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT. Forward-looking statements in this article are subject to risks and uncertainties as described in the company’s SEC filings.
